Disease-Atlas: Navigating Disease Trajectories with Deep Learning. Bryan Lim & Mihaela van der Schaar University of Oxford
|
|
|
- Myron Greene
- 5 years ago
- Views:
Transcription
1 Disease-Atlas: Navigating Disease Trajectories with Deep Learning Bryan Lim & Mihaela van der Schaar University of Oxford
2 Background: Chronic Disease Management Patients with long-term conditions have complex medical needs Requires long-term monitoring and complicated treatment regimens Strong correlation between multimorbidity and age Effective decision support tools required! % of Cohort of Patients with Multimorbidity by Age Group (1) (1) Cassell et al. Br J Gen Pract 12 March The epidemiology of multimorbidity in primary care: a retrospective cohort study.
3 Beyond Simple Prognostic Questions What is the expected rate of lung function deterioration? Is the patient likely to develop any infections or comorbidities? What is the expected survival time of the patient? How do expected outcomes change over time?
4 Beyond Simple Prognostic Questions What is the expected rate of lung function deterioration? Is the patient likely to develop any infections or comorbidities? What is the expected survival time of the patient? How do expected outcomes change over time?
5 Beyond Simple Prognostic Questions What is the expected rate of lung function deterioration? Is the patient likely to develop any infections or comorbidities? What is the expected survival time of the patient? How do expected outcomes change over time?
6 Beyond Simple Prognostic Questions What is the expected rate of lung function deterioration? Is the patient likely to develop any infections or comorbidities? What is the expected survival time of the patient? How do expected outcomes change over time?
7 Beyond Simple Prognostic Questions How long will the patient survive? Clinical biomarkers Not enough! What will happen to the patient in the future? Model the Entire Health Trajectory Predict patterns of decline = Patterns of interactions with healthcare system 7
8 Disease-Atlas Predicting biomarkers. Predicting complications. Predicting infections. Predicting survival.
9 Disease-Atlas Predicting biomarkers. Predicting complications. Predicting infections. Predicting survival.
10 Disease-Atlas Predicting biomarkers. Predicting complications. Predicting infections. Predicting survival.
11 Disease-Atlas Predicting biomarkers. Predicting complications. Predicting infections. Predicting survival.
12 Disease-Atlas Additional Characteristics Personalised based on a patient s unique characteristics and history Predictions over multiple horizons Quantifies uncertainty of forecasts bust to the characteristics o
13 Disease-Atlas Architecture
14 Same Iteration Iteration 2 Multitask Learning Standard (Multivariate) Training Multitask Learning X X X X X
15 Case Study: Cystic Fibrosis Demographic Information Genotypes Survival Annual review data for 10,000+ patients over the period from 2008 to 2015 Lung Health CF Patient Medications Each patient is associated with 87 variables! Lung Infection (Microbiology) Comorbidities (Complications)
16 Survival AUPRC Dynamic Prediction Results Jointly Predicting Mortality as the event-of-interest Results for Mortality Predictions (AUPRC) Lung Function Scores FEV1, Predicted FEV Comorbidities Liver Disease, Asthma, Arthropathy, Bone fracture, Raised Liver Enzymes, Osteopenia, Osteoporosis 11 Infections Burkholderia Cepacia, Pseudomonas Aeruginosa, Haemophilus Influenza, Aspergillus, NTM, Ecoli, Klebsiella Pneumoniae, Gram-Negative, Xanthomonas, Staphylococcus Aureus, ALCA Prediction Horizon (τ) Disease-Atlas LSTM Landmarking JM
17 FEV1 MSE Ave. Comorbidity AUPRC Ave. Infection AUPRC Dynamic Prediction Results FEV1 Results (MSE) Ave. Comorbidity Results (AUPRC) Ave. Infection Results (AUPRC) Prediction Horizon (τ) Prediction Horizon (τ) Prediction Horizon (τ) Disease-Atlas JM Disease-Atlas JM Disease-Atlas JM
18 Web Demo: Use Cases for Clinicians
19 Thank you See you at the poster session!
The Alan Turing Institute. Mihaela van der Schaar Ahmed Alaa
The Alan Turing Institute Mihaela van der Schaar Ahmed Alaa July 18, 2017 The Alan Turing Institute Section A: Vision Section B: CF Registry Data Analysis Section C: Research Agenda Section D: Preliminary
The Role of CPET (cardiopulmonary exercise testing) in Assessing Lung Disease in CF
The Role of CPET (cardiopulmonary exercise testing) in Assessing Lung Disease in CF Dr. Meir Mei-Zahav Kathy and Lee Graub CF Center Schneider CMCI 1 תאריך Exercise in CF You are probably quite sure that
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Liou TG, Adler FR, Cox DR, Cahill BC. Lung transplantation
You Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM
You Can Observe a Lot By Just Watching Wayne J. Morgan, MD, CM Disclosures Genentech Epidemiological Study of Cystic Fibrosis, Scientific Advisory Group CF Foundation Data Safety Monitoring Board Registry/Comparative
Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients
Journal of Cystic Fibrosis 12 (2013) 482 486 www.elsevier.com/locate/jcf Original Article Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients
Torres, Brian Carlmichael L., Ma. Luisa G. Daroy, Juan s. Lopez, Vanessa Oh, Marie Joan Loy, Prospero ma. Tuaño, and Ronald R. Matias Research and
Torres, Brian Carlmichael L., Ma. Luisa G. Daroy, Juan s. Lopez, Vanessa Oh, Marie Joan Loy, Prospero ma. Tuaño, and Ronald R. Matias Research and Biotechnology Division and International Eye Institute
Changes in the management of children with Cystic Fibrosis. Caroline Murphy & Deirdre O Donovan CF Nurses
Changes in the management of children with Cystic Fibrosis Caroline Murphy & Deirdre O Donovan CF Nurses What Is Cystic Fibrosis? Cystic fibrosis (CF) is an inherited chronic disease that primarily affects
Creating a User Defined Pneumonia-Specific Syndrome in ESSENCE. Preventive Medicine Directorate September 2016
Creating a User Defined Pneumonia-Specific Syndrome in ESSENCE Preventive Medicine Directorate September 2016 0 Pneumonia-Specific Syndrome NMCPHC retrospective analyses suggest that surveillance using
Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh
Bronchiectasis Domiciliary treatment Prof. Adam Hill Royal Infirmary and University of Edinburgh Plan of talk Background of bronchiectasis Who requires IV antibiotics Domiciliary treatment Results to date.
CYSTIC FIBROSIS IN AUSTRALIA 2008
CYSTIC FIBROSIS IN AUSTRALIA 2008 11th Annual Report from the Australian Cystic Fibrosis Data Registry Cystic Fibrosis Australia 2010 This work is copyright. Apart from any use as permitted under the Copyright
UK Cystic Fibrosis Registry
UK Cystic Fibrosis Registry Annual Data Report 2017 Scotland UK Cystic Fibrosis Registry 2017 Annual Data Report - Scotland Report prepared by Andrew Lee Statistician Cystic Fibrosis Trust Susan Charman
Cystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS
Cystic Fibrosis Jennifer McDaniel, BS, RRT-NPS Overview Cystic fibrosis is the most common fatal, inherited disease in the U. S. CF results from a defective autosomal recessive gene One copy of gene =
University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology
University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational
AUSTRALIAN CYSTIC FIBROSIS DATA REGISTRY ANNUAL REPORT This publication was produced with the support of Cystic Fibrosis Australia.
AUSTRALIAN CYSTIC FIBROSIS DATA REGISTRY ANNUAL REPORT 2017 This publication was produced with the support of Cystic Fibrosis Australia. CONTENTS FOREWORD 1 INTRODUCTION 2 DATA PERIOD 2 ABBREVIATIONS 2
Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012
Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012 INTRODUCTION PNEUMOTHORAX HEMOPTYSIS RESPIRATORY FAILURE Cystic Fibrosis Autosomal Recessive Genetically
PNEUMONIA IN CHILDREN. IAP UG Teaching slides
PNEUMONIA IN CHILDREN 1 INTRODUCTION 156 million new episodes / yr. worldwide 151 million episodes developing world 95% in developing countries 19% of all deaths in children
Medical / Microbiology
Medical / Microbiology Pseudomonas aeruginosa biofilms in the lungs of Cystic Fibrosis Patients Thomas Bjarnsholt, PhD, Associate professor 1,2, Peter Østrup Jensen, PhD 2 and Niels Høiby, MD, Dr. Med,
Cost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation
Cost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation January 2013 1. A rapid review submission on the drug ivacaftor
Bronchiectasis in Adults - Suspected
Bronchiectasis in Adults - Suspected Clinical symptoms which may indicate bronchiectasis for patients Take full respiratory history including presenting symptoms, past medical & family history Factors
Example of features used to assess asthma (not complete, please see link)
Asthma: diagnosis in adults The 2008 British Thoracic Society guidelinesmarked a subtle change in the approach to diagnosing asthma. This approach is supported in the updated 2011 guidelines. It suggests
NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)
Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Mortality Measures Set
Katherine Ronchetti*, Jo-Dee Tame*, Christopher Paisey, Lena P Thia, Iolo Doull, Robin Howe, Eshwar Mahenthiralingam, Julian T Forton
The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial Katherine Ronchetti*,
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Absidia infections, 324 AccuProbe, for nontuberculous mycobacteria, 282 Achromobacter infections, in cystic fibrosis, 207 208 Acid-fast
Macrolide therapy in cystic fibrosis: new developments in clinical use
Macrolide therapy in cystic fibrosis: new developments in clinical use Clin. Invest. (2013) 3(12), 1179 1186 Macrolide therapy, in particular azithromycin, has been shown to improve aspects of lung health
New(er) Pathogens in Pediatric Respiratory Tract Infections
New(er) Pathogens in Pediatric Respiratory Tract Infections Christopher Doern, PhD, D(ABMM) Associate Director of Microbiology Assistant Professor of Pathology Virginia Commonwealth University Medical
UK Cystic Fibrosis Registry
UK Cystic Fibrosis Registry 2015 Annual Data Report UK Cystic Fibrosis Registry 2015 Annual Data Report An at-a-glance version of this report can be found at www.cysticfibrosis.org.uk/registryreports
The cost-saving, effective diagnoses of melioidosis in Cambodia. Vanaporn Wuthiekanun Faculty of Tropical Medicine Mahidol University
Angkor hospital for Children at Siem Reap The cost-saving, effective diagnoses of melioidosis in Cambodia Vanaporn Wuthiekanun Faculty of Tropical Medicine Mahidol University Angkor Wat Ta Prohm Bayon
Guideline for management of children & adolescents with pleural empyema
CHILD AND ADOLESCENT HEALTH SERVICE PRINCESS MARGARET HOSPITAL FOR CHILDREN Guideline for management of children & adolescents with pleural empyema This guideline provides an evidence-based framework for
Influenza-Associated Pediatric Deaths Case Report Form
STATE USE ONLY DO NOT SEND INFORMATION IN THIS SECTION TO CDC Form approved OMB No. 0920-0007 Last Name: First Name: County: Address: City: State, Zip: Patient Demographics 1. State: 2. County: 3. State
Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis 5/01/2011 CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN.
1938 OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN. American Journal Diseases Children. : The beginning May 1938: 49 cases 25 20 15 Nos of cases 10 5 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 Age
ANNUAL REPORT 2015 AUSTRALIAN CYSTIC FIBROSIS DATA REGISTRY. This publication was produced with the support of Cystic Fibrosis Australia.
AUSTRALIAN CYSTIC FIBROSIS DATA REGISTRY ANNUAL REPORT 2015 This publication was produced with the support of Cystic Fibrosis Australia. AUSTRALIAN CYSTIC FIBROSIS DATA REGISTRY ANNUAL REPORT 2015 1 CONTENTS
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
The ecology of disease interactions in CF
1/44 The ecology of disease in CF University of Utah Department of Mathematics and Department of Biology September 4, 2014 2/44 The big questions in ecology Why are there so many species? Charley Harper
Canadian Cystic Fibrosis Registry
212 Annual Report The Canadian Cystic Fibrosis Registry Cystic Fibrosis Cystic fibrosis (CF) is the most common fatal genetic disease affecting Canadian children and young adults. It is a multi-system
UK Cystic Fibrosis Registry. Annual Data Report 2017
UK Cystic Fibrosis Registry Annual Data Report 2017 Published August 2018 UK Cystic Fibrosis Registry 2017 Annual Data Report An at-a-glance version of this report can be found at cysticfibrosis.org.uk/registryreports
HIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital
HIV AND LUNG HEALTH Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital Introduction HIV infection exerts multiple effects on pulmonary immune responses: Generalised state of immune
A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study,,
Journal of Cystic Fibrosis 15 (2016) 350 356 www.elsevier.com/locate/jcf Original Article A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center
Characterizing aggressiveness and predicting future progression of CF lung disease
Journal of Cystic Fibrosis Volume 8 Suppl 1 (2009) S15 S19 www.elsevier.com/locate/jcf Characterizing aggressiveness and predicting future progression of CF lung disease Michael W. Konstan a, *, Jeffrey
Source: Portland State University Population Research Center (
Neisseria meningitidis Surveillance Report 2009 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated: June 2011 Background The Active
UK Cystic Fibrosis Registry 2014 Annual Data Report
UK Cystic Fibrosis Registry 2014 Annual Data Report Published August 2015 The content of this report may not be used or reproduced in publications without permission of the Cystic Fibrosis Trust. Contents
LRI Children s Hospital
Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval
Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE)
Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE) Dr. Juliane Bernholz, Novartis (Coordinator) Dr. Andrea Appenzeller,
TRANSPARENCY COMMITTEE OPINION. 15 October Date of Marketing Authorisation (national procedure): 16 April 1997, variation of 18 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 October 2008 MERONEM 1 g, powder for solution for IV Injection Box of 10 vials (CIP: 387 830-6) Applicant: ASTRAZENECA
Outbreak Case Study. Ralstonia Outbreak Investigation Background
Outbreak Case Study CAPT Arjun Srinivasan, MD Division of Healthcare Quality Promotion Centers for Disease Control and Prevention Ralstonia Outbreak Investigation Background CDC notified of 5 cases of
Focus on Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis
Focus on (Relates to Chapter 29, Nursing Management: Obstructive Pulmonary Diseases, in the textbook) Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Autosomal recessive, multisystem
How To Assess Severity and Prognosis
How To Assess Severity and Prognosis Gregory Tino, M.D. Chief, Department of Medicine Penn Presbyterian Medical Center Associate Professor of Medicine Perelman School of Medicine at the University of Pennsylvania
Germs are everywhere.
What You Should Know About Germs Germs are everywhere. For people with cystic fibrosis (CF), some germs or pathogens can cause major respiratory or lung infections. This pamphlet explains how germs are
Charles Feldman. Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand
Opportunistic Infections Community Acquired Pneumonia Charles Feldman Professor of Pulmonology and Chief Physician Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand Introduction
PORT CFNZ National Data Registry ~ 1 ~
PORT CFNZ 2014 National Data Registry ~ 1 ~ ~ 2 ~ The Port CFNZ National Data Registry is a research project of Cystic Fibrosis New Zealand. For further information about the CFNZ visit www.cfnz.org.nz
Glossary. Acronyms used in cystic fibrosis peer review reports
Glossary Acronyms used in cystic fibrosis peer review reports Acronym Definition Notes AC(T) Airway clearance (techniques) A term used in physiotherapy ACB Association of Clinical Biochemists Professional
Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015
Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015 1. The cumulative cases report since December 2010 and cases report during January to March 2015 During
Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis
Journal of Cystic Fibrosis 9 (2010) 117 123 www.elsevier.com/locate/jcf Original article Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis Charles R. Esther Jr., Denise
OPAT FOR INFECTION IN BRONCHIECTASIS
OPAT FOR INFECTION IN BRONCHIECTASIS AN AUDIT EVALUATING THE USAGE OF OUTPATIENT ANTIBIOTIC THERAPY FOR INFECTIVE EXACERBATIONS OF BRONCHIECTASIS AGAINST CURRENT BRITISH THORACIC SOCIETY GUIDELINES Dr
Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2017
i Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2017 Jessica R. Spencer and Uzo Chukwuma Approved for public release. Distribution is unlimited. The
Babak Valizadeh, DCLS
Laboratory Diagnosis of Bacterial Infections of the Respiratory Tract Babak Valizadeh, DCLS 1391. 02. 05 2012. 04. 25 Babak_Valizadeh@hotmail.com Biological Safety Cabinet Process specimens in biological
Outbreak investigation of nosocomial infections
Definitions Outbreak investigation of nosocomial infections School of Public Health, HSUM March 2012 Walter Popp, University Clinics Essen, Germany Epidemia increased number of cases, limited in time and
Microbiological surveillance in lung disease in ataxia telangiectasia
Microbiological surveillance in lung disease in ataxia telangiectasia To the Editor: Ataxia telangiectasia is a progressive, neurodegenerative disease causing immunodeficiency, an increased risk of malignancy
Healthcare-associated infections acquired in intensive care units
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Healthcare-associated infections acquired in intensive care units Key facts In 2015, 11 788 (8.3%) of patients staying in an intensive care unit
Efficacy of NaCl nebulized hypertonic solutions in cystic fibrosis
Acta Biomed 2014; Vol. 85, Supplement 4: 10-18 Mattioli 1885 Original article Efficacy of NaCl nebulized hypertonic solutions in cystic fibrosis Azienda Ospedaliero Universitaria Policlinico, DAI Scienze
Clinical and Microbiological Impact of Inhaled Tobramycin Treatment on Cystic Fibrosis Patients with Pseudomonas aeruginosa
JMID/ 2017; 7 (4):178-185 Journal of Microbiology and Infectious Diseases doi: 10.5799/jmid.368802 RESEARCH ARTICLE Clinical and Microbiological Impact of Inhaled Tobramycin Treatment on Cystic Fibrosis
UK Cystic Fibrosis Registry Annual Data Report
UK Cystic Fibrosis Registry 2015 Annual Data Report Published August 2016 UK Cystic Fibrosis Registry 2015 Annual Data Report An at-a-glance version of this report can be found at www.cysticfibrosis.org.uk/registryreports
320 MBIO Microbial Diagnosis. Aljawharah F. Alabbad Noorah A. Alkubaisi 2017
320 MBIO Microbial Diagnosis Aljawharah F. Alabbad Noorah A. Alkubaisi 2017 Pathogens of the Urinary tract The urinary system is composed of organs that regulate the chemical composition and volume of
Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 April - 30 June 2014
Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 April - 3 June 214 1. The cumulative cases report since December 21 and cases report during April to June 214 During 1 April to 3 June
SURVEILLANCE BLOODSTREAM INFECTIONS IN BELGIAN HOPITALS ( SEP ) RESULTS ANNUAL REPORT data
SURVEILLANCE BLOODSTREAM INFECTIONS IN BELGIAN HOPITALS ( SEP ) RESULTS ANNUAL REPORT data 2000-2014 SEP Workgroup Meeting 24 June 2015 Dr. Naïma Hammami Dr. Marie-Laurence Lambert naima.hammami@wiv-isp.be
Delivering personalised care to end of life patients. Jane Naismith Nurse Consultant in Palliative care St Joseph s Hospice London
Delivering personalised care to end of life patients Jane Naismith Nurse Consultant in Palliative care St Joseph s Hospice London Over View This session will cover Supporting patients with long term conditions
A contemporary survival analysis of individuals with cystic fibrosis: a cohort study
ORIGINAL ARTICLE CYSTIC FIBROSIS A contemporary survival analysis of individuals with cystic fibrosis: a cohort study Anne L. Stephenson 1 4, Melissa Tom 2, Yves Berthiaume 5, Lianne G. Singer 4,6, Shawn
NON-CF BRONCHIECTASIS IN ADULTS
Séminaire de Pathologie Infectieuse Jeudi 25 juin 2008 Cliniques Universitaires UCL de Mont-Godinne, Yvoir NON-CF BRONCHIECTASIS IN ADULTS Dr Robert Wilson Royal Brompton Hospital, London, UK Aetiology
Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No
Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No. 0920-0004 STATE USE ONLY DO NOT SEND INFORMATION IN THIS SECTION TO CDC Last Name: First Name: County: Address: City: State,
CYSTIC FIBROSIS REGISTRY
THE CANADIAN CYSTIC FIBROSIS REGISTRY 16 ANNUAL DATA REPORT Canadian Cystic Fibrosis Registry 16 Annual Data Report 1 CYSTIC FIBROSIS Cystic fibrosis (CF) is a rare disease affecting over 4, Canadians
Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis
Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Vallières, E., Tumelty, K., Tunney, M. M., Hannah, R., Hewitt, O., Elborn, J. S., & Downey, D. G. (2017). Efficacy of Pseudomonas
APPENDIX EXHIBITS. Appendix Exhibit A2: Patient Comorbidity Codes Used To Risk- Standardize Hospital Mortality and Readmission Rates page 10
Ross JS, Bernheim SM, Lin Z, Drye EE, Chen J, Normand ST, et al. Based on key measures, care quality for Medicare enrollees at safety-net and non-safety-net hospitals was almost equal. Health Aff (Millwood).
Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
Dutch Cystic Fibrosis Registry
Dutch Cystic Fibrosis Registry Report 2014 NCFS October, 2014 Copyright NCFS 2015 Data from this report may be used for publications and presentations provided the source of information is clearly identified
Management of the Frail Older Patients: What Are the Outcomes
Management of the Frail Older Patients: What Are the Outcomes Professor Edwina Brown Imperial College Renal and Transplant Centre Hammersmith Hospital, London Increasing prevalence of old old on RRT RRT
Haemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014
Haemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014 Background The Active Bacterial Core surveillance (ABCs)
How to Form a Research Question. Insight CF Registry Research Project
How to Form a Research Question Insight CF Registry Research Project Insight CF Registry Research Project Thank you for your interest in the Insight CF Registry Research Project. The goal of this training
QUESTION 1: THE BACTERIUM MOST LIKELY TO BE TRANSMITTED FROM MOTHER TO INFANT DURING LABOR AND CAUSE NEONATAL SEPSIS IS: A. Escherichia coli B.
PRACTICE QUESTIONS QUESTION 1: THE BACTERIUM MOST LIKELY TO BE TRANSMITTED FROM MOTHER TO INFANT DURING LABOR AND CAUSE NEONATAL SEPSIS IS: A. Escherichia coli B. Staphylococcus aureus C. Group B Streptococcus
UK Cystic Fibrosis Registry
UK Cystic Fibrosis Registry 2016 Annual Data Report Scotland UK Cystic Fibrosis Registry 2016 Annual Data Report An at-a-glance version of this report can be found at www.cysticfibrosis.org.uk/registryreports
10/05/2017. Learning Objectives. Etiology and Prevalence. Diagnosis of Cystic Fibrosis. Disease of Childhood? Survival in Cystic Fibrosis
Management of the Cystic Fibrosis Patient Jessica Goggin, MAS, RN Nurse Manager UC San Diego Adult Cystic Fibrosis Program Learning Objectives 1. Describe the symptoms associated with Cystic Fibrosis (CF).
Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function
1 Portex Anaesthesia, Intensive Therapy and Respiratory Unit, UCL, Institute of Child Health, London, UK; 2 Department of Respiratory Medicine, Great Ormond Street Hospital for Children NHS Trust, London,
Clinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults)
Clinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults) Reference: NHS England 1621 First published: Month Year Prepared
Emerging Themes in Epidemiology. Open Access RESEARCH ARTICLE. Dan Li 1, Ruth Keogh 2, John P. Clancy 3 and Rhonda D.
DOI 10.1186/s12982-017-0067-1 Emerging Themes in Epidemiology RESEARCH ARTICLE Open Access Flexible semiparametric joint modeling: an application to estimate individual lung function decline and risk of
ISF criteria (International sepsis forum consensus conference of infection in the ICU) Secondary peritonitis
Appendix with supplementary material. This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Supplementary Tables Table S1. Definitions
Bronchiectasis. What is bronchiectasis? What causes bronchiectasis?
This factsheet explains what bronchiectasis is, what causes it, and how it is diagnosed and managed. More detailed information is available on the Bronchiectasis Patient Priorities website: www.europeanlunginfo.org/bronchiectasis
2016:26: % [1] Frederick Foley 9,600 25% [2,3] DOI: /ICJ
![2016:26: % [1] Frederick Foley 9,600 25% [2,3] DOI: /ICJ](/thumbs/93/114528525.jpg "2016:26: % [1] Frederick Foley 9,600 25% [2,3] DOI: /ICJ")
203 1,3 1,2,3 1 2 3 2016:26:203-209 Frederick Foley 4 95% [1] 9,600 25% [2,3] 105 6 15 105 8 31 201 02-28757462 DOI: 10.6526/ICJ.2016.503 105 10 204 [4-6] ( ) (extraluminal infection) (endogenous) 70%
HYPOCHLOROUS ACID (HOCl) Our Body's immune system protector in a BOTTLE
AQUAOX IS A REVOLUTIONARY DISINFECTION SOLUTION WHICH ACTIVE INGREDIENT HOCL IS NON HAZARDOUS, HAS NO FRAGRANCE, AND IS SAFE ON ALL SURFACES (AND ON SKIN.) HYPOCHLOROUS ACID (HOCl) Our Body's immune system
Retrospective and Prospective Verification of the Cepheid Xpert Flu Assay
JCM Accepts, published online ahead of print on 20 July 2011 J. Clin. Microbiol. doi:10.1128/jcm.01162-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
Clinical and Molecular Genetic Spectrum of Slovenian Patients with CGD
Clinical and Molecular Genetic Spectrum of Slovenian Patients with CGD Avčin T, Debeljak M, Markelj G, Anderluh G*, Glavnik V, Kuhar M University Children s Hospital Ljubljana and *Biotechnical Faculty,
P atients with cystic fibrosis (CF) experience repeated
242 CYSTIC FIBROSIS Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis J Thornton, R Elliott, M P Tully, M Dodd, A K Webb... See end of article
Factors associated with mucoid transition of Pseudomonas aeruginosa in cystic fibrosis patients
ORIGINAL ARTICLE BACTERIOLOGY Factors associated with mucoid transition of Pseudomonas aeruginosa in cystic fibrosis patients B. Martha 1, D. Croisier 1, A. Fanton 2, K. Astruc 3, L. Piroth 1, F. Huet
Palliative and Supportive Care in Cystic Fibrosis
Palliative and Supportive Care in Cystic Fibrosis Dr William Flight Consultant in Respiratory Medicine Oxford Adult Cystic Fibrosis Centre 27 th January 2017 Overview 1. Cystic Fibrosis Clinical Aspects
Dutch Cystic Fibrosis Registy
Dutch Cystic Fibrosis Registy Report 2016 NCFS October 2017 Copyright NCFS 2017 The information from this report can be used for publications and presentations, but only with a reference to the source:
The Bacteriology of Bronchiectasis in Australian Indigenous children
The Bacteriology of Bronchiectasis in Australian Indigenous children Kim Hare, Amanda Leach, Peter Morris, Heidi Smith-Vaughan, Anne Chang Presentation outline What is bronchiectasis? Our research at Menzies
11/19/2012. The spectrum of pulmonary diseases in HIV-infected persons is broad.
The spectrum of pulmonary diseases in HIV-infected persons is broad. HIV-associated Opportunistic infections Neoplasms Miscellaneous conditions Non HIV-associated Antiretroviral therapy (ART)-associated
At-A-Glance report 2014
At-A-Glance report 14 Cystic Fibrosis in Europe Facts and Figures 14 The European Cystic Fibrosis Society Patient Registry (ECFSPR) is happy to present this report with key information about how cystic
THE CANADIAN CYSTIC FIBROSIS REGISTRY
THE CANADIAN CYSTIC FIBROSIS REGISTRY 15 ANNUAL REPORTCanadian Cystic Fibrosis Registry 15 Annual Report 1 CYSTIC FIBROSIS Cystic fibrosis (CF) is a rare disease affecting almost 4, Canadians or roughly
Pulmonary function abnormalities in adult patients with acute exacerbation of bronchiectasis: A retrospective risk factor analysis
Original Article Pulmonary function abnormalities in adult patients with acute exacerbation of bronchiectasis: A retrospective risk factor analysis Chronic Respiratory Disease 2015, Vol. 12(3) 222 229
Rate of pulmonary function decline in South African children with cystic fibrosis
Rate of pulmonary function decline in South African children with cystic fibrosis B M Morrow 1, PhD A C Argent 1,2, FCPaed (SA) G B Distiller 3, MSc (Mathematical Statistics) H J Zar 1, PhD A T R Westwood
At-A-Glance report 2013
At-A-Glance report 213 Cystic Fibrosis in Europe Facts and Figures 213 The European Cystic Fibrosis Society Patient Registry (ECFSPR) is happy to present this report with key information about how cystic
BTS Guideline for non-cf Bronchiectasis
ISSN 2040-2023 July 2010 BTS Guideline for non-cf Bronchiectasis A Quick Reference Guide British Thoracic Society www.brit-thoracic.org.uk BTS GUIDELINE FOR NON-CF BRONCHIECTASIS A QUICK REFERENCE GUIDE